AstraZeneca’s COVID-19 Vaccines 70% Effective
AstraZeneca’s COVID-19 Vaccines 70% Effective. The Lancet released the results of the AstraZeneca vaccine trial, confirming the effectiveness of 70%
Lancet released the results of the AstraZeneca vaccine trial on December 8, confirming its effectiveness of 70%, making it the first vaccine to publish Phase III results in an international medical journal.
The report pointed out that on December 8, Britain became the first country in the West to open a vaccine. She used the vaccine developed by Pfizer and BioNTech. The company reported that the effective rate was 95%. In parallel with Pfizer is the vaccine of Moderna of the United States, which is said to have an effective rate of 94%. AstraZeneca vaccine is the first vaccine to prove its efficacy in a peer-reviewed journal article.
The data of the article shows that a total of 11,636 people were involved in the third phase of clinical trials in the United Kingdom and Brazil. Half of them were vaccinated with two doses (two full-dose groups and the first half-dose group), and the other half received a placebo. A total of 131 people were diagnosed 14 days after the second vaccination, including 30 cases in the vaccine group and 101 cases in the control group, with an average effective rate of 70%.
Data from a total of 23,745 participants in the United Kingdom, Brazil, and South Africa confirmed that the vaccine was safe, and there were no reports of hospitalization or severe illness in the vaccine group. One person in the vaccine group developed transverse myelitis and has recovered.
Andrew Pollard, head of the Oxford Vaccine Group who led the study, said that journals can confirm that we are sharing data “transparently” and reveal the scope of vaccines. This is not a competition between vaccine developers, but a competition between humans and viruses.
The widely questioned problem with vaccines is that the efficacy of the two full-dose vaccinations is 62%, while the first half-dose vaccinations have an efficacy of 90%. Some people think that the half-dose group has a high effective rate, but it does not include people over 55 years old, and its accuracy is questionable. AstraZeneca responded at the press conference that the half-dose vaccination trial was just a mistake.
The Lancet peer review stated that the improvement effect of the half-dose group cannot be attributed to age. Pollard said that we will explain this particular result through more survey data, and the final dose will be determined by the results provided by the regulatory agency.
Simon Clarke, Associate Professor of Cell Microbiology at the University of Reading, commented that AstraZeneca’s test results will create a “dilemma” for regulators: half-dose can provide better protection and reduce the risk of asymptomatic transmission, but the number of the trial group Fewer, and does not include the elderly. If regulators pass this injection program, the protective effect of the elderly who are most vulnerable to the virus remains unclear.
AstraZeneca said in a statement that the company has provided data to regulators around the world and is seeking emergency use authorization from the World Health Organization to accelerate vaccine supply in low-income countries. If approved, 3 billion doses will be produced in 2021. Pollard emphasized that before the population gains universal immunity, it is necessary to continue physical isolation measures and new drug therapies to control the spread of the virus. Vaccines are given priority to people at risk of serious diseases, which may have a major impact on epidemic prevention and control.